Metra, MarcoMarcoMetraTomasoni, DanielaDanielaTomasoniAdamo, MariannaMariannaAdamoAnker, Stefan DStefan DAnkerBayes-Genis, AntoniAntoniBayes-Genisvon Bardeleben, Ralph StephanRalph Stephanvon BardelebenBöhm, MichaelMichaelBöhmDonal, ErwanErwanDonalFilippatos, Gerasimos SGerasimos SFilippatosMaisano, FrancescoFrancescoMaisanoPonikowski, PiotrPiotrPonikowskiSavarese, GianluigiGianluigiSavaresePraz, FabienFabienPrazButler, JavedJavedButler2025-06-122025-06-122025-05-06https://boris-portal.unibe.ch/handle/20.500.12422/210675Mitral regurgitation and tricuspid regurgitation are the most common valvular heart diseases in patients with heart failure and have independent prognostic value. Transcatheter interventions are now available for the treatment of valvular heart disease, and their efficacy and safety have been tested in randomized controlled trials. However, evidence is still limited and sometimes inconclusive because several aspects of these trials limit their interpretation or consistency. These include heterogeneity in the pathogenesis and clinical characteristics of patients, the dynamic nature of secondary atrioventricular valve disease severity, the role of heart failure medications and devices, dependency on procedural results and operators' skills, smaller number of patients enrolled and the power to detect differences in trials, and limitations to use patients' reported outcomes with unblinded study protocols. These specific aspects of trials in patients with atrioventricular valve disease are reviewed in this article with a focus on possible solutions to generate further evidence for the efficacy and safety for transcatheter treatments of atrioventricular valve disease in patients with heart failure.enheart failureheart valve diseasemitral valve insufficiencytricuspid valve insufficiency600 - Technology::610 - Medicine & healtharticle10.48620/884284032402710.1161/CIRCULATIONAHA.124.070411